Added to YB: 2025-01-20
Pitch date: 2025-01-17
RLAY [bullish]
Relay Therapeutics, Inc.
+96.89%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$1.6B
Pitch Price
$4.50
Price Target
21.00 (+137%)
Dividend
N/A
EV/EBITDA
-3.21
P/E
-5.24
EV/Sales
122.62
Sector
Biotechnology
Category
growth
Relay Therapeutics Approaching Deep Value Territory
RLAY: PI3Kα inhibitor RLY-2608 outperforms Scorpion's STX-478 (acquired by LLY for $2.5B). Phase 2 shows 39% ORR, 9.2mo PFS. $840M cash, $4B-$7B market potential. Undervalued at $600M-$700M mkt cap vs. $3B fair value. PT $21. Risks: R&D costs, commercialization timeline.
Read full article (8 min)